Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2016 1
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone.
Lee CK, Gebski VJ, Coates AS, Veillard AS, Harvey V, Tattersall MH, Byrne MJ, Brigham B, Forbes J, Simes RJ; Australia and New Zealand Breast Cancer Trials Group (ANZBCTG). Lee CK, et al. Springerplus. 2013 Aug 21;2:391. doi: 10.1186/2193-1801-2-391. eCollection 2013. Springerplus. 2013. PMID: 24024086 Free PMC article.
Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311.
Ackland SP, Gebski V, Zdenkowski N, Wilson A, Green M, Tees S, Dhillon H, Van Hazel G, Levi J, Simes RJ, Forbes JF, Coates AS; for Breast Cancer Trials Ltd (formerly known as the Australia and New Zealand Breast Cancer Trials Group). Ackland SP, et al. Breast Cancer Res Treat. 2019 Jul;176(2):357-365. doi: 10.1007/s10549-019-05187-y. Epub 2019 Apr 26. Breast Cancer Res Treat. 2019. PMID: 31028610 Clinical Trial.
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Mann GB, Coates AS, Gebski V, Davies L, Thornton R, Reaby L, Cuzick J, Green M; Australia and New Zealand Breast Cancer Trials Group. Zdenkowski N, et al. Ann Oncol. 2016 May;27(5):806-12. doi: 10.1093/annonc/mdw055. Epub 2016 Feb 9. Ann Oncol. 2016. PMID: 26861603 Free article. Clinical Trial.
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, Kannourakis G, Francis PA, Chirgwin J, Abdi E, Gebski V, Veillard AS, Zannino D, Wilcken N, Reaby L, Lindsay DF, Badger HD, Forbes JF; Australia and New Zealand Breast Cancer Trials Group. McCarthy N, et al. Breast. 2014 Apr;23(2):142-51. doi: 10.1016/j.breast.2013.12.001. Epub 2014 Jan 3. Breast. 2014. PMID: 24393617 Free article. Clinical Trial.